Results 91 to 100 of about 106,528 (297)
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono +10 more
wiley +1 more source
Nickoulet Babaei,1 Minka Gill,2,* Mireya Cervantes,3,* Dahyeon Kim,1,* Seanna Yang,4,* Jashin J Wu5 1Loma Linda University School of Medicine, Loma Linda, CA, USA; 2Indiana University School of Medicine, Indianapolis, IN ...
Babaei N +5 more
doaj
Disease severity in moderate‐to‐severe plaque psoriasis: Results from the Belgian REDISCOVER study
Background In the Belgian DISCOVER study, conducted in 2011–2012 before the advent of the IL‐17 and IL‐23 Inhibitors, significant undertreatment of patients with plaque psoriasis was reported.
Tom Hillary +7 more
doaj +1 more source
Lymphocytapheresis in the treatment of psoriasis vulgaris [PDF]
Giancarlo Maria Liumbruno +11 more
openalex +1 more source
Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data [PDF]
Jerry Bagel +8 more
openalex +1 more source
Tocotrienols: A Review From Source to Therapeutic Applications
Tocotrienols demonstrate superior antioxidant, neuroprotective, and anti‐inflammatory properties compared to conventional vitamin E forms, with promising therapeutic applications across multiple disorders when delivered through optimized systems that enhance their inherently limited bioavailability.
Natalia‐Carolina Londoño +6 more
wiley +1 more source
Treatment decisions in psoriasis [PDF]
Michael J Visconti +2 more
openaire +3 more sources

